Efecto del Ginkgo biloba sobre la relación β Amiloide 42/40 Plasmática en Ancianos con Deterioro Cognitivo Leve

Abstract

Mild cognitive impairment (MCI) is a stage between the cognitive impairment in normal aging and demential illness, without functional disability; for treatment that has been used Ginkgo biloba (Gb) that acts as a neuroprotective by blocking the apoptosis, at level cerebral cortex, but which have not been described in detail in Mexican patients. This study examines whether Gb improves plasma biomarkers and imaging in elderly with MCI. The objective of this study was to evaluate effect of Gb on 42/40 Aβ ratio in plasma, risk factors, oxidative stress biomarkers and brain morphological changes in Mexican elderly. Methods. Is an experimental study with Gb, placebo controlled, single-blind and preliminary pilot. Included elderly over 70 years old diagnosed with MCI. The variables analyzed at 0 and 4 months after treatment were: a) Amiloid β 42/40, b) Oxidative Stress (OS), c) Metabolic syndrome (MS) and d) tomographic analysis: cortical atrophy, and atherosclerosis. Results. We identified that patients whit DCL had low levels of schooling; the proportion, while MS and insulin resistance (IR) were higher compared with national average and didn´t change with Gb, as well as the EO. After treatment with Gb, there was a clear tendency to decrease Aβ 42 and Aβ 42/40 ratio, compared with the placebo group; correlated with a cognitive improvement, mainly in the area of memory encoding. Conclusions. Gb improved global cognition, having a positive effect on memory. On the other hand, Gb does not reduce EO and SM.